Eisai Co., Ltd. is a major pharmaceutical company specializing in the research, development, and manufacture of innovative pharmaceuticals. Its primary function is to deliver prescription drugs and th... Eisai Co., Ltd. is a major pharmaceutical company specializing in the research, development, and manufacture of innovative pharmaceuticals. Its primary function is to deliver prescription drugs and therapies aimed at treating neurological disorders, cancer, and other serious diseases, reflecting its strong commitment to human health and well-being. Eisai operates globally, with a robust presence in both advanced and emerging markets, and employs over 10,000 people dedicated to scientific advancement and quality healthcare provision. The company stands out for significant investments in research and development, particularly targeting areas such as Alzheimer’s disease, oncology, and rare diseases, ensuring it remains at the forefront of medical innovation. As part of the health technology sector, Eisai plays a vital role in shaping therapeutic standards and expanding access to high-impact treatments, while maintaining efficient operations and a solid financial structure marked by strong profitability metrics and consistent sales performance. Through its diversified pharmaceuticals and ongoing pipeline development, Eisai is a pivotal contributor to the evolution of global healthcare solutions.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Eisai is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Eisai is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Eisai's data?

Create a free Tracenable account to signal interest in having our team review data for Eisai.

Legal Center Contact Us